253 related articles for article (PubMed ID: 27012389)
1. Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
Karsy M; Guan J; Cohen A; Colman H; Jensen RL
Neurosurg Clin N Am; 2016 Apr; 27(2):249-60. PubMed ID: 27012389
[TBL] [Abstract][Full Text] [Related]
2. Novel therapies for meningiomas.
Wen PY; Drappatz J
Expert Rev Neurother; 2006 Oct; 6(10):1447-64. PubMed ID: 17078786
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
[TBL] [Abstract][Full Text] [Related]
4. Advances in meningioma therapy.
Norden AD; Drappatz J; Wen PY
Curr Neurol Neurosci Rep; 2009 May; 9(3):231-40. PubMed ID: 19348712
[TBL] [Abstract][Full Text] [Related]
5. The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma.
Chamberlain MC
Curr Opin Oncol; 2012 Nov; 24(6):666-71. PubMed ID: 22759739
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy: What is its role in meningioma?
Sherman WJ; Raizer JJ
Expert Rev Neurother; 2012 Oct; 12(10):1189-95; quiz 1196. PubMed ID: 23082735
[TBL] [Abstract][Full Text] [Related]
8. Treatment of unresectable skull base meningiomas with somatostatin analogs.
Schulz C; Mathieu R; Kunz U; Mauer UM
Neurosurg Focus; 2011 May; 30(5):E11. PubMed ID: 21529167
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
[TBL] [Abstract][Full Text] [Related]
10. Meningiomas: Overview and New Directions in Therapy.
Wang N; Osswald M
Semin Neurol; 2018 Feb; 38(1):112-120. PubMed ID: 29548058
[TBL] [Abstract][Full Text] [Related]
11. Current standing and frontiers of gene therapy for meningiomas.
De La Garza-Ramos R; Flores-Rodríguez JV; Martínez-Gutiérrez JC; Ruiz-Valls A; Caro-Osorio E
Neurosurg Focus; 2013 Dec; 35(6):E4. PubMed ID: 24289129
[TBL] [Abstract][Full Text] [Related]
12. New insights into meningioma: from genetics to trials.
Vranic A; Peyre M; Kalamarides M
Curr Opin Oncol; 2012 Nov; 24(6):660-5. PubMed ID: 22820412
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment of recurrent meningiomas.
Chamberlain MC; Barnholtz-Sloan JS
Expert Rev Neurother; 2011 Oct; 11(10):1425-32. PubMed ID: 21955199
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
[TBL] [Abstract][Full Text] [Related]
15. Meningioma.
Fathi AR; Roelcke U
Curr Neurol Neurosci Rep; 2013 Apr; 13(4):337. PubMed ID: 23463172
[TBL] [Abstract][Full Text] [Related]
16. Targeted drug therapy for meningiomas.
Norden AD; Drappatz J; Wen PY
Neurosurg Focus; 2007; 23(4):E12. PubMed ID: 17961036
[TBL] [Abstract][Full Text] [Related]
17. An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas.
Sun SQ; Hawasli AH; Huang J; Chicoine MR; Kim AH
Neurosurg Focus; 2015 Mar; 38(3):E3. PubMed ID: 25727225
[TBL] [Abstract][Full Text] [Related]
18. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
Nassehi D
Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
Dasanu CA; Samara Y; Codreanu I; Limonadi FM; Hamid O; Alvarez-Argote J
J Oncol Pharm Pract; 2019 Apr; 25(3):638-647. PubMed ID: 30253729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
